Authors
Latest:
Beyond “Tech Talent”: New Leadership in Pharma’s Digital AgeWith an increase in digital technology being utilized as a strategic differentiator and business enabler in pharma, where is talent coming from?
Latest:
435 New Medicines in Development for “Older Americans”According to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA), America’s biopharmaceutical research companies are developing 435 new medicines to target 15 leading chronic conditions affecting the Medicare population.
Latest:
Turning Commercial Compliance Roadblocks into a Springboard for InnovationWhile new regulatory requirements are often seen as a roadblock, they also present an opportunity to develop new and innovative solutions.
Latest:
Turning Commercial Compliance Roadblocks into a Springboard for InnovationWhile new regulatory requirements are often seen as a roadblock, they also present an opportunity to develop new and innovative solutions.
Latest:
The Bad Rap on Pharma: In Defense of PatentsA look at drug pricing and patents and the role for patents and how they are under attack.
Latest:
Turning Commercial Compliance Roadblocks into a Springboard for InnovationWhile new regulatory requirements are often seen as a roadblock, they also present an opportunity to develop new and innovative solutions.
Latest:
Cure for the Common Cold Chain BreakIn medicines, as in life, the journey is just as important as the end result
Latest:
How to Communicate About an Ongoing Epidemic of Historic ProportionsThe industry faces a problem of medical education and communication in regards to vaccinations.
Latest:
How to Communicate About an Ongoing Epidemic of Historic ProportionsThe industry faces a problem of medical education and communication in regards to vaccinations.
Latest:
How Rare Disease Marketing Will Stretch Beyond the PatientThe foundation of a strong rare disease marketing program must be built on the comprehensive knowledge of how the life-altering disease impacts all areas of a patient’s life.
Latest:
How Rare Disease Marketing Will Stretch Beyond the PatientThe foundation of a strong rare disease marketing program must be built on the comprehensive knowledge of how the life-altering disease impacts all areas of a patient’s life.
Latest:
California Law Requires Legal, Compliance Scrutiny to Maintain Pharma Data SharingA summary of the key impacts new law, California Consumer Privacy Act (CCPA), will have on business practices related to data flow in specialty pharma, and more.
Latest:
How Cell and Gene Therapy Companies Can Adapt in an Evolving Commercial LandscapeThree changes manufacturers should consider in the wake of COVID-19.
Latest:
California Law Requires Legal, Compliance Scrutiny to Maintain Pharma Data SharingA summary of the key impacts new law, California Consumer Privacy Act (CCPA), will have on business practices related to data flow in specialty pharma, and more.
Latest:
Pharma Outsourcing: Keys to Productivity in 2020sEight lessons to drive better outsourcing decisions.
Latest:
AMCP’s Updated Format V 4.1 has Implications for Manufacturers and PayersAMCP Format Version 4.1 provides manufacturers with additional guidance to communicate evidence about potential new products or new uses to payers in a compliant fashion.
Latest:
Tapping Brazil's PotentialSergio Ricardo Segovia Barbosa looks at Brazil’s growing competitiveness in the biopharma sector.
Latest:
Payer Perspectives on Gene Therapy ReimbursementA follow-up survey of clinical and financial health plan leaders uncovers evolving approaches and views on the management of high-cost, curative-intended treatments with one-time administration.
Latest:
Aligning Contracting to Solve for Payer Risks Is a Win for Biopharma, Payers, and PatientsUpcoming regulatory changes to create new opportunity for specialized offerings.
Latest:
Payer Perspectives on Gene Therapy ReimbursementA follow-up survey of clinical and financial health plan leaders uncovers evolving approaches and views on the management of high-cost, curative-intended treatments with one-time administration.
Latest:
Adapting Biopharma Launches in the COVID-19 LandscapeJudith Kulich and Ben Hohn pose the high priority questions that those teams opting to move forward with a launch, or to move forward after a delay, in the face of the COVID-19 pandemic.
Latest:
Future-Proofing Biopharma Launches Requires Personalizing the Customer ExperienceAs the U.S. economy reopens, engagement with healthcare providers and pharma manufacturers will vary significantly from person to person depending on their comfort level. This article provides insight on how engagement could affect product launches.
Latest:
EMA Launches Data Standards Implementation Guide: The Time to Act is NowThe European Medicines Agency (EMA) has published a guide to implementing IDMP data standards that will be ”a game changer” for the life sciences sector. Remco Munnik, who has been working with the EU focus group creating the EU IDMP Implementation Guide version 2, provides the inside track on the implications for life sciences companies.
